Peptide inhibitor of MMP activity and angiogenesis
AssigneeBeth Israel Deaconess Medical Center, Inc.
InventorsKiflai Bein, Michael Simons
Life of this patent
Estimating the term…
Abstract
The present invention is directed to peptides that interacts with thrombospondin 2 and inhibit matrix metalloproteinase 9 (MMP-9) activity. Consequently, the invention provides peptides that inhibit MMP-9 activity and are useful as inhibitors of angiogenesis and metastasis, among other diseases regulated by MMP-9. The peptides of the invention and their methods of use are therapeutic against diseases, such as cancer and arthritis, which are characterized by neovascularization.
Claims20
An isolated peptide comprising the amino acid sequence shown in SEQ ID NO:1, and conservative substitution variants and homologs thereof.
A fragment of the peptide shown in SEQ ID NO:1, wherein said fragment inhibits MMP-9 activity in an in vitro assay.
An antibody that reacts specifically with an epitope on the peptide shown in SEQ ID NO:
- 1.
An isolated nucleic acid consisting of the sequence shown in SEQ ID NO:
- 2 and any sequence that, but for the degeneracy of the genetic code, would express the peptide shown in SEQ ID NO:1.
A vector comprising the nucleic acid shown in SEQ ID NO:2 and regulatory elements necessary for expression thereof.
A method for treating a disease associated with increased MMP-9 activity.
Dependencies are inferred from the claim text.